Review article: Treatment of Helicobacter pylori infection with ranitidine bismuth citrate- or proton pump inhibitor-based triple therapies

Alimentary Pharmacology and Therapeutics

Volumn 14, Issue 8, 2000, Pages 991-999

  Van Oijen, A H A M ^a   Verbeek, A L ^a   Jansen, J B M J ^a   De Boer, W A ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; CLARITHROMYCIN; PROTON PUMP INHIBITOR; RANITIDINE BISMUTH CITRATE;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ERADICATION THERAPY; GRAM NEGATIVE INFECTION; HELICOBACTER PYLORI; HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SIDE EFFECT;

AMOXICILLIN; ANTI-BACTERIAL AGENTS; ANTI-ULCER AGENTS; BISMUTH; CLARITHROMYCIN; DRUG RESISTANCE, MICROBIAL; DRUG THERAPY, COMBINATION; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; NITROIMIDAZOLES; PENICILLINS; PROTON PUMPS; RANITIDINE; TREATMENT OUTCOME;

EID: 0033852605     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.2000.00798.x     Document Type: Review

References (48)

1. 1 Lind T, Veldhuyzen-van ZS, Unge P, et ed. Eradication of Helicobacter pylori using one-week triple therapies combining omeprazole with two antimicrobials: the MACH I Study. Helicobacter 1996; 1: 138-44.
2. 2 Anonymous. Current European concepts in the management of Helicobacter pylori infection. The Maastricht Consensus Report. European Helicobacter Study Group. [Published erratum appears in Gut 1997; 41: 276]. Gut 1997; 41: 8-13.
3. 3 Pare P, Farley A, Romaozinho JM, Bardhan KD, French PC, Roberts PM. Comparison of ranitidine bismuth citrate plus clarithromycin with omeprazole plus clarithromycin for the eradication of Helicobacter pylori. Aliment Pharmacol Ther 1999; 13: 1071-8.
4. 4 Megraud F, Pichavant R, Palegry D, French PC, Roberts PM, Williamson R. Ranitidine bismuth citrate (RBC) co-prescribed with clarithromycin is more effective in the eradication of Helicobacter pylori than omeprazole with clarithromycin. Gut 1997; 41: A92(Abstract).
5. 5 Laine L, Estrada R, Trujillo M, Emami S. Randomized comparison of ranitidine bismuth citrate-based triple therapies for Helicobacter pylori. Am J Gastroenterol 1997; 92: 2213-5.
6. 6 Savarino V, Mansi C, Mele MR, et al. A new 1-week therapy for Helicobacter pylori eradication: ranitidine bismuth citrate plus two antibiotics. Aliment Pharmacol Ther 1997; 11: 699-703.
7. 7 Cammarota G, Cannizzaro 0, Tursi A, et al. One-week therapy for Helicobacter pylori eradication: ranitidine bismuth citrate plus medium-dose clarithromycin and either tinidazole or amoxycillin. Aliment Pharmacol Ther 1998; 12: 539-43.
8. 8 de-Boer WA, Haeck PW, Otten MH, Mulder CJ. Optimal treatment of Helicobacter pylori with ranitidine bismuth citrate (RBC): a randomized comparison between two 7-day triple therapies and a 14-day dual therapy. Am J Gastroenterol 1998; 93: 1101-7.
9. 9 Malfertheiner P, Megraud F, O'Morain CA. Efficacy of ranitidine bismuth citrate (RBC) dual and triple therapies for the eradication of Helicobacter pylori. Gut 1998; 42: 596-7.
10. 10 Laheij RJ, Rossum LG, Jansen JB, Straatman H, Verbeek AL. Evaluation of treatment regimens to cure Helicobacter pylori infection - a meta-analysis. Aliment Pharmacol Ther 1999; 13: 857-64.
11. 11 Pipkin GA, Williamson R, Wood JR. Review article: one-week clarithromycin triple therapy regimens for eradication of Helicobacter pylori. Aliment Pharmacol Ther 1998; 12: 823-37.
12. 12 Savarino V, Zentilin P, Pivari M, et al. The impact of antibiotic resistance on the efficacy of three 7-day regimens against H. pylori infection. Gastroenterology 1999; 116: A302-3 (Abstract).
13. 13 Miettinen OS. Theoretically Epidemiology, Principles of Occurrence Research in Medicine New York: Delmar Publishing, 1985.
14. 14 Sung JJ, Leung WK, Ling TK, et al. One-week use of ranitidine bismuth citrate, amoxycillin and clarithromycin for the treatment of Helicobacter pylori-related duodenal ulcer. Aliment Pharmacol Ther 1998; 12: 725-30.
15. 15 Catalano F, Catanzaro R, Bentivegna C, Brogna A, Condorelli G, Cipolla R. Ranitidine bismuth citrate versus omeprazole triple therapy for the eradication of Helicobacter pylori and healing of duodenal ulcer. Aliment Pharmacol Ther 1998; 12: 59-62.
16. 16 Spadaccini A, De-Fanis C, Sciampa G, Pantaleone U, Di-Virgilio M, Pizzicanella G. Lansoprazole or ranitidine bismuth citrate based triple therapies for Helicobacter pylori eradication: results of an open randomized study. Aliment Pharmacol Ther 1998; 12: 997-1001.
17. 17 Aydin A, Gunsar F, Yilmaz M, et al. Omeprazole, lansoprazole or ranitidine bismuth citrate in combination with amoxicillin plus clarithromycin in Helicobacter pylori eradication. Gut 1998; 43(Suppl. 2): A89(Abstract).
18. 18 Cabooter M, Dekkers CP, Theodors A, Vanweerts S. Ranitidine bismuth citrate (RBC) or omeprazole (O) with clarithromycin (C) and amoxicilline (A) for one week in the eradication of H. pylori. Gastroenterology 1999; 116: A345(Abstract).
19. 19 Georgopoulos S, Karatapanis S, Ladas S, et al. Lansoprazole (LAN) vs ranitidine bismuth citrate (RBC) based short-term triple therapies for Helicobacter pylori (H. pylori) eradication: a randomized study with 6 month follow-up. Gut 1999; 45: A120(Abstract).
20. 20 Herrerias JM. Efficacy and cost study in Portugal and Spain of three different 7-day eradication regimes of Helicobacter pylori. Gastroenterology 1999; 116: A186(Abstract).
21. 21 Mao HV, Lak BV, Chung NQ, et al. Omeprazole or ranitidine bismuth citrate with clarithromycin and amoxicillin for 10 days to treat H. pylori infection: a randomized, controlled trial in Vietnamese patients with duodenal ulcer. Gastroenterology 1999; 116: A136(Abstract).
22. 22 Ravizza M, Suriani R, Puglisi F, et al. Helicobacter pylori eradication: RBC plus different antibiotic regimens evaluation in short term therapy. Gut 1998; 43: A85(Abstract).
23. 23 Spinzi G, Boni F, Ballardini G, Venturelli R, Prada A, Minoli G. One-week therapy with omeprazole (PPI) or ranitidine bismuth citrate and two antibiotics for eradication of H. pylori in duodenal ulcer (DU): interim report of a multicenter study. Gastroenterology 1999; 116: A317(Abstract).
24. 24 Gisbert JP, Carpio D, Marcos JL, et al. Pantoprazole vs. ranitidine bismuth citrate plus two antibiotics for H. pylori eradication. Gut 1999; 45: A108(Abstract).
25. 25 Buzas GM, Szekely E, Illyes G, Szeles I. One week triple regimens using lansoprazole or ranitidine bismuth citrate for Helicobacter pylori (HP) eradication. Abstract at the 41st annual meeting of the Hungarian Society of Gastroenterology, Balaton Liga, 1999.
26. 26 Delia-Cave M, Beneduci F, Vitale LM, et al. Ranitidine bismuth citrate is equally effective as omeprazole in the eradication of Helicobacter pylori infection in non-ulcer dyspepsia. Gastroenterology 1998; 114: A100(Abstract).
27. 27 Ojetti V, Gasbarrini A, Pitocco D, et al. Efficacy of different eradication regimens in insulin dependent diabetes mellitus patients affected by Helicobacter pylori. Gastroenterology 1999; 116: A270(Abstract).
28. 28 van't-Hoff BW, van-der-Hulst RW, van-der-Ende A, Ten-Kate FJ, Houben MH, Tytgat GN. Ranitidine bismuth citrate vs omeprazole in combination with clarithromycin and metronidazole in a one week regimen against Helicobacter pylori infection. Gut 1999; 45: A111(Abstract).
29. 29 Susi D. Cost and efficacy of 7-day triple therapies for H.p. eradication: PPI-based vs. RBC-based treatments. Gut 1999; 45: A106(Abstract).
30. 30 Egger M, Davey-Smith G. Meta-analysis. Principles and procedures. Br Med J 1997; 315: 1371-4.
31. 31 Stewart LA, Parmar MKB. Meta-analysis of the literature or of individual patient data; is there a difference? Br Med J 1993; 314: 418-22.
32. 32 Axon A. Treatment of Helicobacter pylori: where are we now? What are the key questions? Eur J Gastroenterol Hepatol 1999; 11: S3-7.
33. 33 Huang JQ, Wilkinson JM, Chiba N, Hunt RH. The importance of clarithromycin dose in the management of Helicobacter pylori infection: a meta-analysis of triple therapies with a proton pump inhibitor, clarithromycin and amoxicillin or metronidazole. Aliment Pharmacol Ther 1999; 13: 719-29.
34. 34 Wurzer H, Rodrigo L, Stamler D, et al. Short-course therapy with amoxycillin-clarithromycin triple therapy for 10 days (ACT-10) eradicates Helicobacter pylori and heals duodenal ulcer. ACT-10 Study Group. Aliment Pharmacol Ther 1997; 11: 943-52.
35. 35 Ducons JA, Santolaria S, Guirao R, Ferrero M, Montoro M, Gomollon F. Impact of clarithromycin resistance on the effectiveness of a regimen for Helicobacter pylori: a prospective study of 1-week lansoprazole, amoxycillin and clarithromycin in active peptic ulcer. Aliment Pharmacol Ther 1999; 13: 775-80.
36. 36 Graham DY. Antibiotic resistance in Helicobacter pylori: implications for therapy. Gastroenterology 1998; 115: 1272-7.
37. 37 van-der-Wouden EJ, Thijs JC, Zwet AA, Kooy A, Kleibeuker JH. The influence of metronidazole resistance on the efficacy of ranitidine bismuth citrate triple therapy regimens for Helicobacter pylori infection. Aliment Pharmacol Ther 1999; 13: 297-302.
38. 38 Goddard AF, Logan RP, Lawes S, Spiller RC. Randomized controlled comparison of nitroimidazoles for the eradication of Helicobacter pylori and relief of ulcer-associated and non-ulcer dyspepsia. Aliment Pharmacol Ther 1999; 13: 637-42.
39. 39 Buckley MJ, Xia HX, Hyde DM, Keane CT, O'Morain CA. Metronidazole resistance reduces efficacy of triple therapy and leads to secondary clarithromycin resistance. Dig Dis Sci 1997; 42: 2111-5.
40. 40 van der Wouden EJ, Thijs JC, van Zwet AA, Sluiter WJ, Kleibeuker JH. The influence of in vitro nitroimidazole resistance on the efficacy of nitroimidazole-containing anti-Helicobacter pylori regimens: a meta-analysis. Am J Gastroenterol 1999; 94: 1751-9.
41. 41 Bazzoli F, Berretti D, De-Luca L, et al. What can be learnt from the new data about antibiotic resistance? Are there any practical clinical consequences of Helicobacter pylori antibiotic resistance? Eur J Gastroenterol Hepatol 1999; 11(Suppl. 2): S39-42.
42. 42 de-Boer WA, Tytgat GN. Treatment of Helicobacter pylori infection. Br Med J 2000; 320: 31-4.
43. 43 Goddard AF, Logan RP, Atherton JC, Hawkey CJ, Spiller RC. Maastricht consensus report regimen for second line treatment of H. pylori infection: how does it perform in practice? Gut 1997; 41(Suppl. 1): A104(Abstract).
44. 44 Weissfeld A, Haber M, Rose P, Kidd S, Siejman N. Geographical distribution in the United States of primary resistance to clarithromycin and metronidazole in patients infected with Helicobacter pylori. Gastroenterology 1997; 112: A328 (Abstract).
45. 45 Megraud F. Resistance of Helicobacter pylori to antibiotics: the main limitation of current proton-pump triple therapy. Eur J Gastroenterol Hepatol 1999; 11(Suppl. 2): S35-7.
46. 46 Houben MH, van der Beek D, Hensen EF, Craen AJ, Rauws EA, Tytgat GN. A systematic review of Helicobacter pylori eradication therapy - the impact of antimicrobial resistance on eradication rates. Aliment Pharmacol Ther 1999; 13: 1047-55.
47. 47 Huelin Benítez J, Jiménez Pérez M, Durán Campos A, et al. Quadruple therapy with omeprazole, tetracycline, metronidazole and bismuth as a second option after failure of a first eradication therapy. Gut 1998; 43(Suppl. 2): A86(Abstract).
48. 48 Borda F, Martinez A, Echarri A, Jimenez J, Rodrguez C, Jara C. Clinical practice results of quadruple treatment in Helicobacter pylori eradication failure with OCA-7. Gut 1998; 43(Suppl. 2): A81(Abstract).